HC Wainwright Forecasts Strong Price Appreciation for Tempus AI (NASDAQ:TEM) Stock

Tempus AI (NASDAQ:TEM) had its price objective boosted by stock analysts at HC Wainwright from $68.00 to $85.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright‘s price objective would indicate a potential upside of 8.31% from the company’s previous close.

TEM has been the subject of several other reports. Roth Capital initiated coverage on Tempus AI in a research report on Tuesday, September 8th. They issued a “neutral” rating and a $67.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Tempus AI in a report on Wednesday, September 2nd. They set an “overweight” rating and a $80.00 target price on the stock. Piper Sandler upgraded shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their target price for the stock from $56.00 to $76.00 in a report on Tuesday, September 1st. UBS Group assumed coverage on shares of Tempus AI in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $70.00 price target on the stock. Finally, Weiss Ratings upgraded shares of Tempus AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, October 13th. Eleven investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $79.37.

Tempus AI Stock Up 8.7%

Shares of NASDAQ:TEM opened at $78.48 on Tuesday. Tempus AI has a one year low of $40.77 and a one year high of $90.53. The company has a 50 day moving average of $70.80 and a 200-day moving average of $57.12. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The stock has a market cap of $14.16 billion, a price-to-earnings ratio of -54.50 and a beta of 3.54.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Monday, November 2nd. The company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.16. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%. The firm’s revenue was up 23.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.46) earnings per share. On average, sell-side analysts forecast that Tempus AI will post -1.45 earnings per share for the current year.

Insider Buying and Selling

In other Tempus AI news, CEO Eric Lefkofsky sold 250,000 shares of the company’s stock in a transaction on Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total transaction of $19,367,500.00. Following the sale, the chief executive officer directly owned 100,000 shares of the company’s stock, valued at approximately $7,747,000. This represents a 71.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO James Rogers sold 26,313 shares of the company’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $60.00, for a total transaction of $1,578,780.00. Following the completion of the sale, the chief financial officer directly owned 106,024 shares in the company, valued at approximately $6,361,440. The trade was a 19.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,256,777 shares of company stock worth $86,356,352 over the last 90 days. Company insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Tempus AI by 23.4% in the first quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares in the last quarter. Amova Asset Management Americas Inc. raised its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock worth $195,549,000 after buying an additional 821,490 shares in the last quarter. Eagle Health Investments LP bought a new stake in shares of Tempus AI during the 1st quarter worth $11,588,000. Aristotle Atlantic Partners LLC bought a new stake in shares of Tempus AI during the 1st quarter worth $6,179,000. Finally, International Assets Investment Management LLC boosted its stake in Tempus AI by 3,027.6% in the third quarter. International Assets Investment Management LLC now owns 104,555 shares of the company’s stock valued at $8,563,000 after buying an additional 101,212 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Tempus reported adjusted earnings of $0.07 per share versus the expected $0.09 loss, while revenue rose 23.1% year over year to $411.54 million, slightly above the $409.39 million consensus. The narrower loss and strong top-line growth were the primary catalysts for the stock’s advance. Tempus Reports Third Quarter 2026 Results
• Positive Sentiment: Management raised its 2026 revenue outlook. Tempus now expects approximately $1.60 billion to $1.605 billion in 2026 revenue and continues to target about $65 million in adjusted EBITDA. Investors were encouraged by growth in the Data and Applications segment, which expanded 33% and carries gross margins above 71%, as well as the company’s collaboration with Bristol Myers Squibb. Tempus 2026 Revenue Outlook
• Positive Sentiment: Analyst and trading signals improved. Needham raised its price target from $75 to $89 and maintained a Buy rating. Trading activity also showed elevated call-option demand, while Cathie Wood’s Ark Investment Management reportedly purchased about $11.2 million of TEM shares, adding to bullish sentiment.
• Neutral Sentiment: Analyst views remain mixed. UBS reiterated a Hold rating with an $80 price target, citing solid oncology execution but weaker hereditary testing. This suggests the earnings beat was encouraging, but some analysts remain cautious about the pace and quality of growth. Tempus UBS Rating
• Negative Sentiment: Personalis acquisition risks remain. Reports highlight potential challenges integrating Personalis, including execution complexity and the possibility that deal-related costs or operational disruption could weigh on future performance. Personalis Integration Risks

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.